Assistant Professor LIU Chuang
Ph.D. in Materials Physics and Chemistry, University of Chinese Academy of Sciences, China
Postdoctoral fellow, Brigham and Women’s Hospital, Harvard Medical School, USA
Department of Pharmacy and Pharmaceutical Sciences, National University of Singapore
18 Science Drive 4, Singapore 117543
Office: S9-06-02B
Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore
Tel: +65 6516 2648
Fax: +65 6779 1554
Email: chuangliu@nus.edu.sg
Research website
Google Scholar
|
2026/01– Present
|
Assistant Professor (Tenure track) Department of Pharmacy and Pharmaceutical Sciences, Faculty of Science, National University of Singapore Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore |
|
2021/06 – 2025/12 |
Research Fellow / Research Scientist Department of Neurosurgery, Center for Stem Cell and Translational Immunotherapy, Department of Anaesthesiology, Center for Nanomedicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA. |
|
2016/09 – 2021/06 |
Ph.D. in Materials Physics and Chemistry Ningbo Institute of Materials Technology and Engineering, Chinese Academy of Sciences. University of Chinese Academy of Sciences, China. |
|
2020/01 – 2021/06 |
Visiting Ph.D. Student Department of Anaesthesiology, Center for Nanomedicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA. |
- Chuang Liu, Xiangang Huang, Kok-Siong Chen, Sihan Xiong, Alexey V Yaremenko, Xueyan Zhen, Xinru You, Filippo Rossignoli, Yi Tang, Seyoung Koo, Wei Chen, Na Kong, Tian Xie, Khalid Shah, Wei Tao*. Systemic reprogramming of tumour immunity via IL-10-mRNA nanoparticles. Nature Nanotechnology (2025), 20, 1526–1538.
- Chuang Liu#, Qiangqiang Shi#, Xiangang Huang, Seyoung Koo, Na Kong*, Wei Tao*. mRNA-based cancer therapeutics. Nature Reviews Cancer (2023), 23, 526–543.
- Chuang Liu#, Alexey V. Yaremenko#, Xiaolong Li#, Xinru You, Xiaoyu Zhu, Nuo Liu, Wei Chen, Na Kong, Tian Xie, Gaurav D. Gaiha*, Robert Langer, and Wei Tao*. mRNA technology for the prevention and treatment of HIV-1 infection. Nature Reviews Bioengineering (2025). doi: 10.1038/s44222-025-00387-2.
- Chuang Liu*. mRNA-based enzyme replacement for propionic acidaemia. Nature Reviews Endocrinology (2025), 21, 526. (*corresponding author)
- Chuang Liu, Khalid Shah*. Taming CAR T cell therapy toxicity. Nature Materials (2023), 22, 1444–1445. (*corresponding author)
- Sihan Xiong, Chuang Liu*. Breaking the PEG barrier to boost mRNA-LNP therapeutics. Nature Reviews Materials (2025), 10, 799-800. (*corresponding author)
- Sihan Xiong, Chuang Liu*. Core mission: mRNA endosomal escape. Nature Reviews Chemistry (2025), 9, 433. (*corresponding author)
- Sihan Xiong, Khalid Shah*, Chuang Liu*. A zwitterionic twist. Nature Reviews Chemistry (2024), 8, 721. (*corresponding author)
- Xiangang Huang#, Chuang Liu#, Na Kong, Yufen Xiao, Arif Yurdagul, Ira Tabas, Wei Tao*. Synthesis of siRNA nanoparticles to silence plaque-destabilizing gene in atherosclerotic lesional macrophages. Nature Protocols (2022), 17, 748–780. (#co-first authors)
Chuang Lab (Laboratory for Gene Medicine) is a multidisciplinary research team dedicated to unlocking the power of genetic science to develop the next generation of therapies. Our research interests lie in immunotherapy, particularly for cancer, using modalities such as mRNA, gene-engineered cells and bacteria, and oncolytic viruses.
For instance, mRNA technology enables the rapid and cost-effective production of diverse vaccines and therapeutics compared to conventional approaches, leading to a surge of interest in recent years. In oncology, many of the mRNA-based therapeutics have demonstrated promising efficacy in preclinical studies, with several advancing to clinical trials. Building on the demonstrated safety and effectiveness of clinically approved mRNA vaccines, and fueled by growing enthusiasm across the biomedical field, mRNA technology is poised to become a cornerstone in the development of next-generation cancer therapies.
By bridging fundamental discovery with translational innovation, we strive to make curative genetic medicines a reality.